Switch to:
Valeant Pharmaceuticals International Inc (NYSE:VRX)
EV/EBIT
49.46 (As of Today)

EV/EBIT ratio is calculated as enterprise value divided by its Earnings Before Interest and Taxes (EBIT). As of today, Valeant Pharmaceuticals International Inc's enterprise value is $37,749 Mil. Valeant Pharmaceuticals International Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was $763 Mil. Therefore, Valeant Pharmaceuticals International Inc's EV/EBIT ratio for today is 49.46.

VRX' s EV/EBIT Range Over the Past 10 Years
Min: -1217.7   Max: 379.7
Current: 48.98

-1217.7
379.7

During the past 13 years, the highest EV/EBIT Ratio of Valeant Pharmaceuticals International Inc was 379.70. The lowest was -1217.70. And the median was 12.85.

VRX's EV/EBIT is ranked lower than
83% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.31 vs. VRX: 48.98 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt). Valeant Pharmaceuticals International Inc's enterprise value for the quarter that ended in Jun. 2016 was $37,231 Mil. Valeant Pharmaceuticals International Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was $763 Mil. Valeant Pharmaceuticals International Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2016 was 2.05%.


Definition

Valeant Pharmaceuticals International Inc's EV/EBIT for today is calculated as:

EV/EBIT=Enterprise Value (Today)/Earnings Before Interest and Taxes (EBIT) (TTM)
=37749.161/763.3
=49.46

Valeant Pharmaceuticals International Inc's current Enterprise Value is $37,749 Mil.
Valeant Pharmaceuticals International Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was 414.5 (Sep. 2015 ) + 192.2 (Dec. 2015 ) + 60.9 (Mar. 2016 ) + 95.7 (Jun. 2016 ) = $763 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

This is a more accurate valuation of companies' operation because it consider the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt).

Valeant Pharmaceuticals International Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2016 is calculated as:

Earnings Yield (Joel Greenblatt) (Q: Jun. 2016 )=EBIT (TTM)/Enterprise Value (Q: Jun. 2016 )
=763.3/37230.7242
=2.05 %

Valeant Pharmaceuticals International Inc's Enterprise Value for the quarter that ended in Jun. 2016 was $37,231 Mil.
Valeant Pharmaceuticals International Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2016 was 414.5 (Sep. 2015 ) + 192.2 (Dec. 2015 ) + 60.9 (Mar. 2016 ) + 95.7 (Jun. 2016 ) = $763 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Related Terms

Enterprise Value, Earnings Yield (Joel Greenblatt), Earnings Before Interest and Taxes (EBIT)


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Valeant Pharmaceuticals International Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
ev2ebit -13.197.0510.9311.53-76.6567.91312.36-123.4132.2048.74

Valeant Pharmaceuticals International Inc Quarterly Data

Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16
ev2ebit -219.97-1,171.7042.1732.2044.8450.2248.7548.7439.5647.21
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK